Language: BG BG
← Back to results
Recruiting Phase 1 NCT07156201

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years

Phase 1 – testing safety in a small group of people
Conditions: KCNT1-Related Epilepsy

Sponsor: Actio Biosciences, Inc.

trial.available_in: БГ
Overview
This first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy participants.
Description
This is a Phase 1a, first-in-human, placebo-controlled study consisting of 3 parts. Part 1 is a single ascending dose (SAD) study in up to 32 participants consisting of a screening period of up to 28 days prior to a single dose of ABS-1230 or placebo, with follow-up 7 days and 14 days after dosing. Part 2 is a multiple ascending dose (MAD) study in up to 30 participants consisting of a screening period of up to 28 days, followed by ABS-1230 or placebo once daily for 14 days, with follow-up 7 days and 14 days after dosing is completed. Part 3 is a food effect (FE) study in 12 participants consisting of two doses of ABS-1230 under fasted and fed conditions and in combination with omeprazole with follow-up 7 days and 14 days after dosing is completed.
Who can participate
Inclusion Criteria: * Age 18 to 55 years, inclusive * Body mass index greater than or equal to 18 to less than or equal to 32 kg/m2 * Medically healthy with no clinically significant medical history, physical examination, vital sign, standard 12-lead ECG, chemistry, hematology, urinalysis, or coagulation results at Screening as deemed by the Investigator * Male and female subjects must use adequate birth control and agree not to donate sperm or eggs for the time periods specified in the protocol Exclusion Criteria: * Positive result for HIV, HBV, or HCV * History of malignancy other than treated basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the cervix * History of alcoholism or recreational drug use within 2 years or a positive alcohol or tobacco test result at screening or first check-in visit * For female participants, must not be pregnant, breastfeeding, or seeking to become pregnant while in the study
Locations 1
Australia (1)
Scientia Clinical Research
Sydney , New South Wales
Technical details
Status
Recruiting
Phase
Phase 1
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Maximum age
55 Years
Healthy volunteers
No
Start date
28.08.2025
Completion date
01.03.2026
Registry ID
NCT07156201
Source
anzctr
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.